Association Between Angiotensin Receptor Blocker Use and Cardiovascular Outcomes Compared With Angiotensin-Converting Enzyme Inhibitors in Patients With Atherosclerotic Cardiovascular Disease: A Real-World Cohort Study
Listen to this summary
The authors aimed to evaluate the association between angiotensin receptor blocker (ARB) use and cardiovascular outcomes compared to angiotensin-converting enzyme inhibitor (ACEI) use in patients with atherosclerotic cardiovascular disease (ASCVD). Their findings from a large retrospective cohort study indicated that ARB users experienced a lower incidence of major adverse cardiovascular events (MACE) and individual components such as ischemic stroke and all-cause mortality compared to ACEI users. However, the authors caution that these results should be interpreted as non-causal, suggesting that differences in treatment patterns and patient characteristics may influence the outcomes.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Mayo Clinic proceedings
View all →Jun 24, 2026 · Mayo Clinic proceedings
Evaluation of the Preclinical and Clinical Obesity Framework for Risk Stratification of Major Adverse Liver Outcomes
Jun 24, 2026 · Mayo Clinic proceedings
Lumbar Puncture in the 21st Century: an Imaging-Based Primer to Determine Procedural Safety
Jun 24, 2026 · Mayo Clinic proceedings
Association of Obesity With Mortality and Bleeding in Cancer-Associated Venous Thromboembolism
Jun 23, 2026 · Mayo Clinic proceedings
The Physiological Basis of Acute GFR Decline With Renoprotective Therapies
Jun 22, 2026 · Mayo Clinic proceedings
Estimating the Cost of Poor Work Control Among Physicians in the United States
Jun 16, 2026 · Mayo Clinic proceedings
Hyponatremia: A Mechanistic Approach to Diagnosis and Management
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
